Changes in oral anticoagulant and cardiovascular drug use with the progression of neurodegenerative disorders

Cardiovascular diseases are communal among radical surviving with Alzheimer's illness (AD) and Parkinson's illness (PD). Understanding cause utilization patterns successful these populations is important for ensuring harmless and effectual treatment, supporting objective decision-making and improving the wide attraction of radical surviving with AD and PD. However, small is known astir however the usage of oral anticoagulants and cardiovascular drugs changes during the progression of these disorders.